Refine
Has Fulltext
- yes (66)
Is part of the Bibliography
- yes (66)
Year of publication
Document Type
- Journal article (65)
- Conference Proceeding (1)
Language
- English (66)
Keywords
- adrenocortical carcinoma (9)
- obesity (5)
- metabolomics (4)
- 18F-FDG (3)
- CXCR4 (3)
- Cushing’s syndrome (3)
- FGFR (3)
- PET (3)
- adrenocortical cancer (3)
- biomarker (3)
- cortisol (3)
- hypercortisolism (3)
- liraglutide (3)
- paraganglioma (3)
- pheochromocytoma (3)
- positron emission tomography (3)
- therapy (3)
- vandetanib (3)
- ACTH (2)
- C-X-C motif chemokine receptor 4 (2)
- CYP2W1 (2)
- Cushing’s disease (2)
- FGF-pathway (2)
- PPGL (2)
- Positronen-Emissions-Tomografie (2)
- TKI (2)
- [68Ga]PentixaFor (2)
- adenomas (2)
- adrenal cancer (2)
- adrenal tumours (2)
- adrenocortical tumors (2)
- cancer (2)
- carcinomas (2)
- cardiovascular events (2)
- chemokine receptor (2)
- endoradiotherapy (2)
- gastric bypass (2)
- immune response (2)
- immunohistochemistry (2)
- immunotherapy (2)
- machine learning (2)
- medullary thyroid carcinoma (2)
- mitotane (2)
- mortality (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- peptide tyrosine tyrosine (PYY) (2)
- prognosis (2)
- recurrence (2)
- theranostics (2)
- treatment (2)
- tyrosine kinase inhibitor (2)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- ALT (1)
- ATRX (1)
- Adrenocortial carcinomas (1)
- Antigen 4 (1)
- Autoimmune-Diseases (1)
- BIRC7 (1)
- BRAF(V600E) mutation (1)
- Biochemical-Diagnosis (1)
- C-terminal HSP90 inhibitors (1)
- CCR7 (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cell lung canger (1)
- Contrast-enhanced CT (1)
- Copeptin (1)
- Cushing (1)
- Cushing's disease (1)
- Cushings syndrome (1)
- Dendritic Cells (1)
- Diagnosis (1)
- Disease prevalence (1)
- EMT (1)
- F-18-FDG PET/CT (1)
- FGF21 (1)
- FGFR-inhibitors (1)
- Fibroblast Growth Factor-21 (1)
- FoxP3 Expression (1)
- GLP-1 (1)
- Immune-System (1)
- Immunological Self-Tolerance (1)
- Klotho-related molecules (1)
- LND (1)
- LNE (1)
- MASS (1)
- MR (1)
- MTL30 (1)
- Medicine (1)
- Medizin (1)
- Medullärer Schilddrüsenkrebs (1)
- Men (1)
- Metanephrine (1)
- Methodological quality (1)
- Multiple-Sclerosis (1)
- N-terminal HSP90 inhibitors (1)
- NAFLD (1)
- NASH (1)
- NMR (1)
- NOP10 (1)
- NR3C1 (1)
- Normetanephrine (1)
- PD-L1 (1)
- PF-05231023 (1)
- PYY3-36 (1)
- Paraganglioma (1)
- Plasma (1)
- Positron-emission-tomography (1)
- RNA Expression (1)
- RNAScope (1)
- RYGB (1)
- Resistance (1)
- Roux-en-Y Gastric Bypass (1)
- Roux-en-Y gastric bypass (1)
- Roux-en-Y gastric bypass surgery (1)
- SNP (1)
- SOAT1 (1)
- Sex-Hormones (1)
- Society (1)
- Spin echo (1)
- Suppressive Function (1)
- Systemic-Lupus-Erythematosus (1)
- TERT (1)
- Test accuracy (1)
- USP8 (1)
- Utility (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [18F]FDG-PET-CT (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- abdominal lymph node metastases (1)
- adjuvant platinum-based chemotherapy (1)
- adjuvant treatment (1)
- adrenal (1)
- adrenal cortex hormones (1)
- adrenal cortex neoplasms (1)
- adrenal gland (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenal surgery (1)
- adrenal tumor (1)
- adrenal tumors (1)
- adrenalectomia (1)
- adrenocortical (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical development (1)
- adrenocortical tissues (1)
- aldosterone (1)
- association (1)
- autoantibodies (1)
- autonomous cortisol secretion (1)
- balance (1)
- bioinformatic clustering (1)
- biomarker prediction (1)
- biomarkers (1)
- blood pressure (1)
- branched-chain amino acids (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer treatment (1)
- cancer-testis antigens (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiovascular risk factors (1)
- caspase-3 (1)
- catecholamines (1)
- catenin (1)
- cells (1)
- cholesterol metabolism (1)
- chromosomes (1)
- circulating microRNA (1)
- combination (1)
- comparability (1)
- comparative genomic hybridization (1)
- complication (1)
- confounders (1)
- copeptin (1)
- cortisol-producing adenoma (1)
- cytoplasmic staining (1)
- deubiquitinases (1)
- dexamethasone suppression test (1)
- diabetes insipidus (1)
- diagnosis (1)
- disease score (1)
- disease severity (1)
- dissection (1)
- distant metastases (1)
- dogs (1)
- drug therapy (1)
- early prognosis (1)
- ectopic (1)
- efficacy (1)
- endogenous hypercortisolism (1)
- epithelial markers (1)
- expression (1)
- feature selection (1)
- focused surgical approach (1)
- follow-up (1)
- genetic loci (1)
- glucocorticoid excess (1)
- guidelines (1)
- high dose dexamethasone suppression test (1)
- high-resolution analysis (1)
- hormones (1)
- hypothalamic gene expression (1)
- imaging (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immunity (1)
- immunohistochemistry techniques (1)
- in silico analysis (1)
- insulin resistance (1)
- intragastric balloon (1)
- isturisa (1)
- kidney disease (1)
- kinase (1)
- kinases (1)
- liquid chromatography–tandem mass spectrometry (LC–MS/MS) (1)
- livin (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lymphocytes (1)
- malignant tumors (1)
- management (1)
- mass spectrometry (1)
- mass spectronomy (1)
- medical therapy (1)
- mesenchymal markers (1)
- meta-analysis (1)
- metyrapone (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- miR-483-5p (1)
- miRNA (1)
- molecular diagnostics (1)
- morbidity (1)
- multicenter (1)
- multiple myeloma (1)
- mutation (1)
- mutation triggers (1)
- neuroblastoma – diagnosis (1)
- neutral loss (1)
- normal adrenal glands (1)
- normal values (1)
- notch signaling (1)
- nuclear staining (1)
- operation (1)
- osilodrostat (1)
- osmotic stimulation (1)
- outcome (1)
- paired (1)
- papillary (1)
- papillary thyroid carcinoma (PTC) (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- pathogenesis (1)
- patient survival (1)
- pediatric (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pembrolizumab (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- personalized medicine (1)
- phosphatidylcholines (1)
- phosphorylation (1)
- pituitary adenomas (1)
- pituitary gland (1)
- plasma (1)
- plasma NMR (1)
- polarization (1)
- preanalytical conditions (1)
- precision medicine (1)
- predictive marker (1)
- primary hyperparathyroidism (1)
- primary polydipsia (1)
- prognostic biomarker (1)
- prognostic factors (1)
- prognostic marker (1)
- prospective (1)
- prostate cancer (1)
- protein expression (1)
- radical resection (1)
- radioiodine (1)
- radioiodine therapy (1)
- radiotherapy (1)
- radiotherapy (RT) (1)
- recurrence free survival (1)
- recurrence-free survival (1)
- reference data (1)
- repeated surgery (1)
- review (1)
- rodent model (1)
- rygb (1)
- selpercatinib (1)
- serum (1)
- signs and symptoms (1)
- sleeve gastrectomy (1)
- somatic mutations (1)
- sphingolipids (1)
- steroid measurement (1)
- sudden cardiac death (1)
- super-obesity (1)
- surgery (1)
- surgical oncology (1)
- surgical treatment (1)
- t-lymphocytes (1)
- targeted metabolomics (1)
- targeted treatment (1)
- telomeres (1)
- thyroid carcinoma (TC) (1)
- timing (1)
- transgenic rats (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumors (1)
- tyrosine kinase inhibitor (TKI) (1)
- unsupervised clustering (1)
- urine (1)
- volume (1)
Institute
- Medizinische Klinik und Poliklinik I (66) (remove)
Sonstige beteiligte Institutionen
Background:
Recent decades have seen a rise in the incidence of well-differentiated (mainly papillary) thyroid carcinoma around the world. In Germany, the age-adjusted incidence of well-differentiated thyroid carcinoma in 2010 was 3.5 per 100 000 men and 8.7 per 100 000 women per year.
Method:
This review is based on randomized, controlled trials and multicenter trials on the treatment of well-differentiated thyroid carcinoma that were retrieved by a selective literature search, as well as on three updated guidelines issued in the past two years.
Results:
The recommended extent of surgical resection depends on whether the tumor is classified as low-risk or high-risk, so that papillary microcar cinomas, which carry a highly favorable prognosis, will not be overtreated. More than 90% of localized, well-differentiated thyroid carcinomas can be cured with a combination of surgery and radioactive iodine therapy. Radio active iodine therapy is also effective in the treatment of well-differentiated thyroid carcinomas with distant metastases, yielding a 10-year survival rate of 90%, as long as there is good iodine uptake and the tumor goes into remission after treatment; otherwise, the 10-year survival rate is only 10%. In the past two years, better treatment options have become available for radioactive-iodine-resistant thyroid carcinoma. Phase 3 studies of two different tyrosine kinase inhibitors have shown that either one can markedly prolong progression-free survival, but not overall survival. Their more common clinically significant side effects are hand-foot syndrome, hypertension, diarrhea, proteinuria, and weight loss.
Conclusion:
Slow tumor growth, good resectability, and susceptibility to radioactive iodine therapy lend a favorable prognosis to most cases of well-differentiated thyroid carcinoma. The treatment should be risk-adjusted and interdisciplinary, in accordance with the current treatment guidelines. Even metastatic thyroid carcinoma has a favorable prognosis as long as there is good iodine uptake. The newly available medical treatment options for radioactive-iodine-resistant disease need to be further studied.